Nifty Pharma News and Updates

Keep track of all breaking news on Nifty Pharma from all sources in a single place.

Load latest

Granules India Ltd.

05 Mar 2025

503.25

1.41%

Granules India Fails To Follow US FDA Mandated Safety Procedures

NDTV Profit

The US FDA said there were violation of current good manufacturing practice regulations for finished pharmaceuticals, at Granules India's Gagillapur facility.

Granules India Ltd. has an average target of 682.00 from 5 brokers.

Granules India Ltd.

04 Mar 2025

503.25

1.41%

LIC raises stake in Granules India to 5.02%. Do you own?

livemint

Granules India share price has declined by 16.55% over the past month and over 20% on a year-to-date (YTD) basis. In the last six months, the pharma stock has dropped more than 32%.

Granules India Ltd. is trading below all available SMAs

Glenmark Pharmaceuticals Ltd.

02 Mar 2025

1489.80

0.21%

Glenmark Pharma Recalls 15 Lakh Bottles Of ADHD Medication In US: FDA

NDTV Profit

The recall is due to the 'presence of N-Nitroso Atomoxetine impurity above the FDA-recommended limit'.

Glenmark Pharmaceuticals Ltd. has gained 61.82% in the last 1 Year

Glenmark recalls 1.5 million bottles of ADHD medication in US: USFDA

Business Standard | 02 Mar 2025

Cipla Ltd.

28 Feb 2025

1517.00

1.19%

Tariffs should not determine how Indian drugmakers operate: Cipla CEO

Business Standard

India, often dubbed the "pharmacy of the world", is among the top exporters to the U.S., especially for cheaper versions of popular drugs

Cipla Ltd. is trading above its 100 day SMA of 1477.9

Biocon Ltd.

28 Feb 2025

341.85

-0.01%

Biocon launches drug Liraglutide for diabetes, Biolide for obesity in UK

Business Standard

Biotechnology firm Biocon on Friday said it has launched a product for diabetes and obesity management in the UK. The GLP-1 peptide, Liraglutide, will be marketed in the UK under the brand names Liraglutide Biocon for diabetes and Biolide for chronic weight management, the company said in a statement. The launch follows the approval from the Medicines and Healthcare Products Regulatory Agency (MHRA), UK, earlier this year, making Biocon Ltd the first generics company to obtain approval for gLiraglutide in a major regulated market, it added. "The timely launch will offer healthcare providers and patients affordable access to this drug and help fulfil an unmet need," Biocon CEO and MD Siddharth Mittal said. The company will continue to focus its efforts towards expanding the reach of gLiraglutide into other European markets, the US and select geographies, he added. Glucagon-like peptide-1 (GLP-1) are medications that help lower blood sugar levels and promote weight loss. Liraglutid

Biocon Ltd. has gained 39.10% in the last 1 Year

Biocon Launches Diabetes, Obesity Management Drug In UK

NDTV Profit | 28 Feb 2025

Granules India Ltd.

28 Feb 2025

503.25

1.41%

Granules India shares tumble almost 8% after USFDA issues warning letter for its Gagillapur facility

livemint

Granules India's shares fell nearly 8% after the US FDA issued a warning letter regarding its Gagillapur facility, citing four concerns. The company confirmed progress in addressing these issues while maintaining product distribution.

Granules India Ltd. is trading below all available SMAs

Granules India Share Price Hits Over Eight-Month Low After US FDA Issues Warning

NDTV Profit | 28 Feb 2025

Mankind Pharma Ltd.

28 Feb 2025

2220.00

2.70%

Mankind Pharma gets NCLT nod for amalgamation of Shree Jee Lab, JPR Labs, Jaspack

livemint

The National Company Law Tribunal has approved the amalgamation of Shree Jee Laboratory, JPR Labs, and Jaspack Industries with Mankind Pharma.

Mankind Pharma Ltd. is trading below all available SMAs

Glenmark Pharmaceuticals Ltd.

27 Feb 2025

1489.80

0.21%

Glenmark Pharma Launches Epinephrine Injection In US

NDTV Profit

The injection is used to increase mean arterial blood pressure in adult patients with hypotension associated with septic shock and also for emergency treatment of allergic reactions.

Glenmark Pharmaceuticals Ltd. is trading above its 50 day SMA of 1431.8

Mankind Pharma Ltd.

26 Feb 2025

2220.00

2.70%

Mankind Pharma sets sights on Novo Nordisk's anti-obesity drug Semaglutide

Business Standard

The firm is focusing on specialty chronic therapies like immunotherapy, antibody-drug conjugates, and gene therapy drugs, besides peptides like Glucagon-like peptide-1 (GLP-1)